These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 31473836)

  • 1. Can Direct Oral Anticoagulants Be Used for Stroke Prevention Among Patients with Valvular Atrial Fibrillation?
    Anderson SL; Marrs JC
    Curr Cardiol Rep; 2019 Aug; 21(10):118. PubMed ID: 31473836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct oral anticoagulant use in nonvalvular atrial fibrillation with valvular heart disease: a systematic review.
    Owens RE; Kabra R; Oliphant CS
    Clin Cardiol; 2017 Jun; 40(6):407-412. PubMed ID: 28004413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of 'valvular' atrial fibrillation: results of the European Heart Rhythm Association Survey.
    Potpara TS; Lip GY; Larsen TB; Madrid A; Dobreanu D; Jędrzejczyk-Patej E; Dagres N;
    Europace; 2016 Oct; 18(10):1593-1598. PubMed ID: 27876696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral anticoagulation for stroke prevention amongst atrial fibrillation patients with valvular heart disease: an update.
    Ha AC; Verma A; Verma S
    Curr Opin Cardiol; 2017 Mar; 32(2):174-180. PubMed ID: 27861189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease.
    Dawwas GK; Barnes GD
    Curr Cardiol Rep; 2022 Jun; 24(6):731-738. PubMed ID: 35460473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial.
    De Caterina R; John Camm A
    Europace; 2016 Jan; 18(1):6-11. PubMed ID: 26450845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Bioprosthetic Heart Valves.
    Duan L; Doctor JN; Adams JL; Romley JA; Nguyen LA; An J; Lee MS
    Am J Cardiol; 2021 May; 146():22-28. PubMed ID: 33529622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to define valvular atrial fibrillation?
    Fauchier L; Philippart R; Clementy N; Bourguignon T; Angoulvant D; Ivanes F; Babuty D; Bernard A
    Arch Cardiovasc Dis; 2015 Oct; 108(10):530-9. PubMed ID: 26184867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct-acting oral anticoagulants in patients with atrial fibrillation and valvular heart disease.
    Canales N; Cao T; Fakourfar N; Snee M; Tsu L
    JAAPA; 2022 Sep; 35(9):17-18. PubMed ID: 36007114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
    De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
    Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B;
    Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stroke Prevention in Atrial Fibrillation: The Role of Oral Anticoagulation.
    Mtwesi V; Amit G
    Med Clin North Am; 2019 Sep; 103(5):847-862. PubMed ID: 31378330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel oral anticoagulants and valvular atrial fibrillation: are they always contraindicated?
    Di Pasquale G; Zagnoni S; Riva L
    Intern Emerg Med; 2015 Feb; 10(1):21-4. PubMed ID: 25589164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antithrombotic treatment of patients with valvular atrial fibrillation].
    Bovin A; Christensen TD; Grove EL
    Ugeskr Laeger; 2017 Jul; 179(29):. PubMed ID: 28789760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation).
    Thomas KL; Jackson LR; Shrader P; Ansell J; Fonarow GC; Gersh B; Kowey PR; Mahaffey KW; Singer DE; Thomas L; Piccini JP; Peterson ED
    J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29273635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and an Aortic Bioprosthetic Valve.
    Miyake M; Takegami M; Obayashi Y; Amano M; Kitai T; Fujita T; Koyama T; Tanaka H; Ando K; Komiya T; Izumo M; Kawai H; Eishi K; Yoshida K; Kimura T; Nawada R; Sakamoto T; Shibata Y; Fukui T; Minatoya K; Tsujita K; Sakata Y; Kimura T; Sugio K; Takita A; Iwakura A; Tamura T; Nishimura K; Furukawa Y; Izumi C;
    Circ J; 2022 Oct; 86(11):1699-1707. PubMed ID: 35811134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of oral anticoagulants in complex clinical situations with atrial fibrillation.
    Gullón A; Sánchez Fuentes D; López-de-Sá E; Martí-Almor J; Barón-Esquivias G; Jiménez López J; Del Mar Contreras Muruaga M; Suárez Fernández C
    Med Clin (Barc); 2018 Jun; 150 Suppl 1():8-24. PubMed ID: 30502871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term oral anticoagulation for atrial fibrillation in low and middle income countries.
    Ramakumar V; Benz AP; Karthikeyan G
    Indian Heart J; 2021; 73(2):244-248. PubMed ID: 33865530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.